Related Experiment Video

Updated: Jul 18, 2026

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

Optimizing therapy of seizures in patients with HIV and cysticercosis

A I Bhigjee1, S Rosemberg

  • 1Department of Neurology, Inkosi Albert Luthuli Central Hospital, Mayville 4058, South Africa. Bhigjee@ukzn.ac.za

Neurology
|December 28, 2006
PubMed

Insights

Managing seizures in HIV and neurocysticercosis (NCC) requires careful antiepileptic drug (AED) selection. Newer AEDs are preferred for HIV patients on antiretroviral (ARV) therapy to avoid drug interactions, while older AEDs effectively manage NCC seizures.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Millions worldwide live with HIV or neurocysticercosis (NCC), both conditions frequently causing recurrent seizures.
  • Seizures in HIV stem from various neurological complications, including lesions, meningitis, encephalitis, and ischemia.
  • Neurocysticercosis-related seizures can manifest across all stages of cyst development.

Purpose of the Study:

  • To outline the challenges in managing seizures in patients with HIV and neurocysticercosis (NCC).
  • To discuss appropriate antiepileptic drug (AED) selection, considering drug-drug interactions with antiretroviral (ARV) treatments in HIV patients.
  • To review the efficacy of antiparasitic drugs in preventing chronic epilepsy in NCC.

Main Methods:

  • Review of seizure mechanisms in HIV and NCC.
  • Analysis of antiepileptic drug (AED) choices and potential interactions with antiretroviral (ARV) therapy.
  • Evaluation of antiparasitic drug efficacy in neurocysticercosis (NCC).

Main Results:

  • HIV-associated seizures necessitate careful AED selection due to potential drug-drug interactions with ARV regimens, favoring newer AEDs with simpler pharmacokinetics.
  • Older AEDs are effective for controlling seizures in neurocysticercosis (NCC).
  • Evidence suggests antiparasitic drug use in active NCC reduces the risk of developing chronic epilepsy.

Conclusions:

  • Antiepileptic drug (AED) management for HIV patients requires careful consideration of antiretroviral (ARV) interactions.
  • Neurocysticercosis (NCC) seizures are manageable with established AEDs.
  • Antiparasitic therapy is beneficial in preventing long-term epilepsy in neurocysticercosis (NCC).

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...